Clinical trials
Hemophilia A clinical trials
Below are recruiting hemophilia a clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04817462Recruiting
Liver biopsy in people with haemophilia gene therapy
This study takes a small liver tissue sample (a liver biopsy) in men who previously received haemophilia gene therapy. The goal is to learn more about how the gene therapy works and how safe it is for the liver.
LondonAges 18–80 - NCT07523399Recruiting
Joint Health and Balance in Adults with Hemophilia A
This study looks at how hemophilia A affects joint health, balance, and quality of life in adults. Researchers will assess your joints and balance to understand the relationship between joint damage and everyday function.
VanAges 18–65 - NCT07416526RecruitingPhase 3
Testing NXT007 for hemophilia A without inhibitors
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
Aurora, ColoradoAges 12 years+ - NCT07416604RecruitingPhase 3
Study of NXT007 vs emicizumab for hemophilia A
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
Orange, CaliforniaAges 12 years+ - NCT07406139RecruitingPhase 4
PCC treatment for hemophilia A with inhibitors
This trial tests a clotting factor product called PCC (prothrombin complex concentrate) to treat bleeding episodes in people with hemophilia A who have developed inhibitors. It's for those who are 12–65 and have frequent joint bleeds.
Tianjin, Tianjin MunicipalityAges 12–65 - NCT05454774RecruitingEarly Phase 1
Gene therapy for adults with severe hemophilia A
This early-phase study tests an FVIII gene therapy to help your body make more of the missing clotting factor in hemophilia A. It’s aimed at adults with severe low FVIII levels who have already used FVIII replacement products for a long time and have not developed an immune blocker (an inhibitor).
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05709288RecruitingPhase 1
Gene therapy for teens with hemophilia B
This Phase 1 study tests a one-time gene therapy treatment (BBM-H901) for boys ages 12 to 18 with hemophilia B. It aims to see if the treatment is safe and can help the body make more clotting factor over time.
Tianjin, Tianjin MunicipalityAges 12–18 - NCT06238908RecruitingEarly Phase 1
Gene therapy NGGT003 for severe hemophilia A
This early-phase trial tests a new gene therapy called NGGT003 for men with severe hemophilia A. It aims to see if the treatment is safe and can help reduce bleeding episodes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05641610RecruitingPhase 1/Phase 2
Study drug for adults with hemophilia B who still bleed
This Phase 1/2 study tests ZS801, a gene-related treatment, to see how safe it is and whether it helps prevent bleeding in adults with hemophilia B. You may be considered if you’ve had frequent bleeds or joint problems and meet several lab and health requirements.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05630651Recruiting
ZS801 for adults with severe hemophilia B
This trial studies ZS801, a gene therapy, in adults with hemophilia B who have very low natural FIX (a clotting protein) and frequent bleeding or joint problems. It aims to see how well it works and whether it is safe, especially by monitoring blood counts, infections, and immune responses.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT05888870RecruitingPhase 4
Testing a treatment for hemophilia A with inhibitor antibodies
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
TianjinAges 14–65 - NCT06864975RecruitingPhase 4
Different doses of ADVATE for immune tolerance in boys with hemophilia A and inhibitors
This trial tests how different doses and schedules of the factor VIII medicine ADVATE can train the immune system to accept factor VIII again in boys with hemophilia A who have developed inhibitors. The goal is to find a better way to help their bodies stop blocking the treatment.
Beijing, Beijing MunicipalityAges birth–18 years - NCT07314983Recruiting
Long-term blood thinning in severe hemophilia A
This study looks at using long-term blood thinners (anticoagulants) in adults with severe hemophilia A, a bleeding disorder. It aims to understand if this treatment can be safe and effective for patients who may need it.
StrasbourgAges 18 years+ - NCT07285460RecruitingPhase 3
Fitusiran for young boys with hemophilia A or B
This trial tests if fitusiran, given as a shot, can help prevent bleeding in boys ages 1 to 12 with severe hemophilia (factor VIII under 1% or factor IX at 2% or lower). It includes boys with or without inhibitors and aims to understand safety and how well it works.
Los Angeles, CaliforniaAges 1–11 - NCT07259356Enrolling by invitation
Blood-flow-restriction training for hemophilia patients
This trial tests whether a special type of exercise that limits blood flow is safe and possible for people with hemophilia. It might help strengthen muscles without causing joint bleeds.
Bonn, North Rhine-WestphaliaAges 18 years+ - NCT07226206RecruitingPhase 1/Phase 2
Gene therapy for adults with severe hemophilia A
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
Orange, CaliforniaAges 18 years+ - NCT07099313Recruiting
Hemophilia treatment burden and daily life study
This study looks at how prophylactic treatment for hemophilia affects your daily life, sleep, and feelings about your health. It compares different types of clotting factor concentrates to see if one is easier to manage than the other.
Oviedo, Principality of AsturiasAges 18 years+ - NCT07101926Recruiting
Monitoring anti-TFPI in severe hemophilia patients on Marstacimab
This study looks at how a medicine called Marstacimab affects your body's natural anti-clotting protein (TFPI) in people with severe hemophilia A or B who are already taking it. It involves blood tests to see how well the treatment works.
BronAges 18 years+ - NCT07080905RecruitingPhase 3
Gene therapy study for teens with severe hemophilia B
This study tests a one-time gene therapy (CSL222) for teenage boys with severe or moderately severe hemophilia B. It aims to help their bodies produce the clotting factor they need, potentially reducing or eliminating the need for regular factor infusions.
Orange, CaliforniaAges 11.5 years–17.2 years - NCT06992076Recruiting
Hemophilia patients' experience with marstacimab treatment
This registry study follows people with hemophilia A or B who are taking marstacimab as their regular preventive treatment. It aims to understand how the medicine works in real life and how patients feel during treatment.
Xiamen, FujianAges 12 years+ - NCT06120582RecruitingPhase 1/Phase 2
Gene therapy safety study for severe hemophilia B
This study tests a new gene therapy called ANB-002 for men with severe hemophilia B (factor IX levels at or below 2%). The goal is to see if it's safe and how well it might help your blood clot normally.
HomyelAges 18 years+ - NCT06833983RecruitingPhase 3
Study of GS1191-0445 injection for hemophilia A
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
Hefei, AnhuiAges 18–65 - NCT06816953Enrolling by invitation
Joint health in severe hemophilia A with prophylaxis
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
Bangkok, PatumwanAges Any age - NCT06809972Recruiting
Understanding joint lining changes on ultrasound in hemophilia
This study uses ultrasound to check if thickened joint lining (synovium) in people with severe hemophilia is a sign of active inflammation or just a harmless leftover. It may help doctors decide whether to treat or watch these joints.
UtrechtAges 12 years+
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hemophilia a?
- Yes. Clin2 currently lists 87 recruiting hemophilia a studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hemophilia a trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hemophilia a trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.